Cipla Limited (CIPLA) — Financial Results | 25 July 2025

· NSE 🔴 High Importance ✨ Positive
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings

Cipla reported consolidated revenue of ₹6,957 crores for Q1 FY26, up 4% YoY, with EBITDA margin steady at 25.6% and PAT rising 10% YoY to INR 1,298 crores. One India business crossed INR 3,000 crores in revenue for the first time, while North America delivered $226 Mn revenue from differentiated assets including launches of Nano Paclitaxel and Nilotinib. Africa grew 11% YoY in USD, and Emerging Markets and Europe grew 8% YoY. R&D investment stood at INR 432 crores (6.2% of sales).

📄 View Original Announcement (PDF)

About Cipla Limited (CIPLA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,15,682.55 Cr P/E: 25.4 ROE: 14.6% ROCE: 19.4%

View full CIPLA stock details →

📡 Get AI alerts when CIPLA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CIPLA — Free

📊 More CIPLA filings

See all CIPLA filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CIPLA files new disclosures

Track CIPLA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track CIPLA — Free

Free account · 2 AI queries/day